Modality
siRNA
MOA
MALT1i
Target
IL-13
Pathway
Ferroptosis
FTDOCD
Development Pipeline
Preclinical
~Jul 2012
→ ~Oct 2013
Phase 1
~Jan 2014
→ ~Apr 2015
Phase 2
~Jul 2015
→ ~Oct 2016
Phase 3
Jan 2017
→ Jun 2028
Phase 3Current
NCT05674237
413 pts·OCD
2021-09→TBD·Terminated
NCT08376076
2,867 pts·FTD
2023-06→2028-06·Active
NCT07649136
547 pts·FTD
2017-01→TBD·Completed
+1 more trial
6,497 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-05-061.1y awayPh3 Readout· OCD
2028-06-112.2y awayPh3 Readout· FTD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Complet…
P3
Active
P3
Termina…
P3
Active
Catalysts
Ph3 Readout
2027-05-06 · 1.1y away
OCD
Ph3 Readout
2028-06-11 · 2.2y away
FTD
ActiveCompletedTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05674237 | Phase 3 | OCD | Terminated | 413 | FEV1 |
| NCT08376076 | Phase 3 | FTD | Active | 2867 | SeizFreq |
| NCT07649136 | Phase 3 | FTD | Completed | 547 | eGFR |
| NCT04800534 | Phase 3 | OCD | Active | 2670 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 |